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1. Introduction  
For decades, platelet concentrates have been a standard transfusion component for the 
treatment of clotting disorders. They are prepared from the whole blood within 24 hours 
from collection from voluntary blood donors by means of differential centrifugation of 
platelet rich plasma (PRP) or by the apheresis and stored at room temperature with a 
maximum shelf life of 7 days. They are transfused to the patients who suffer from 
thrombocytopenia or some other platelet disorder in order to sustain the haemostatic 
function. Freezing platelets is feasible but results in poor recovery, although the platelets 
retain their clotting functions after thawing. The use of platelets is permanently increasing, 
due to advanced surgical and other therapies and they are considered vital products in 
blood banking today (Brecher, 2005). 
Apart from their clotting functions, platelets have been shown to possess some other 
evolutionary highly conserved biological functions, such as immune defence, tissue forming 
and regeneration. These properties are now clinically used by the virtue of platelet gel 
preparations. Technically, the clinical precursor of platelet gel has been fibrin glue that was 
composed of two separate solutions - fibrinogen and thrombin. When mixed together, these 
agents were similar to the last stages of the clotting cascade in forming a fibrin clot. 
Fibrinogen has been obtained from pooled allogeneic single-donor plasma units and from 
the autologous blood of the patients and has been usually isolated by the process of 
cryoprecipitation. The additional thrombin component has been generally derived from 
commercial bovine sources. Some investigators have even added calcium chloride and/or 
antifibrinolytics (i.e., aminocaproic acid, aprotinin) to their preparations in order to enhance 
the clot formation. Although fibrin glue has been used in a variety of surgical procedures for 
the prevention of bleeding, it has been especially useful in heparinized patients undergoing 
cardiovascular procedures requiring extracorporeal circulation, as it does not need an intact 
hemostatic system to be effective. Fibrin glue has also been evaluated in the presealing of 
woven or knitted Dacron vascular grafts. The major drawback to its use has been attributed 
to the potential risk of transmitted serological disease from pooled and single-donor blood 
donors, so the patient's own blood was considered to be the safest preparation to prepare 
fibrin glue. Overall, fibrin glue is a useful adjunct to other methods to control bleeding in 
selected surgical patients (Thompson et al., 1988; Lee & Kang, 2011). 
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Autologous platelet rich plasma, which is by the activation of platelets converted to platelet gel 
(PG) was developed in the early 1970s as a by-product of multicomponent apheresis. The first 
published paper relating to the use of platelet-fibrinogen-thrombin mixture as a ˝corneal 
adhesive˝ is dated from 1975 ( Rosenthal et al., 1975). In 1979, a report was published about 
platelet gel ˝gel foam˝ used to obtain sutureless nerve anastomosis (Fischer, 1979). Another 
publication in 1980, described the role of fibrin to drive fibroblast migration and collagen 
deposition and leading to granulation tissue formation (Brandstedt et al., 1980).  
Articles published in the 1990s provided numerous insights into the basic mechanisms of 
the physiologic process of healing after injury had occurred. Some of the results provided by 
these papers were that fibroblasts are recruited at the injury site by soluble factors; that the 
platelet releasate contains a high level of chemotactic factors that recruit fibroblasts in a 
strictly dose-dependent manner, that the fibroblasts migrate along a fibrin-rich matrix; and 
that fibronectin is necessary for such migration to occur since it provides a conduit for 
transmigration. In their migration, fibroblasts adhere to the fibronectin fibres through 
alpha5beta1 and alpha5beta3 receptors. Proteases are necessary for fibroblast transmigration 
through the fibrin-rich matrix (the role of metalloproteases was depicted some years later). 
Interestingly, the fibrin/ fibronectin fibres retain growth factors released from the activated 
platelets within the injured site (Greiling & Clark, 1997). 
In 1996, the physiological relationship between mesenchymal cells, fibrin and growth factors 
was shown to result in the establishment of granulation tissue. It was demonstrated that the 
formation of granulation tissue is strongly enhanced by the platelet releasate. The platelet 
releasate provides continuous stimulation for mesenchyme-derived cells to interact with 
fibrin, thus accelerating the development of granulation tissue (McClain et al., 1996). It is 
now confirmed that the human platelet lysate can induce the expansion of human 
mesenchymal stem cells in vitro, which will by omitting the animal derived albumin, change 
the cell cultivation approaches for regenerative medicine.  
One of the first disciplines that readily accepted the new regenerative capacity of the 
PRP/PG was the maxillofacial surgery (Schallmoser et al., 2007). PRP was introduced to the 
maxillofacial community by Whitman et al. as an alternative to the fibrin glue in 1997 
(Whitman et al., 1997). Marx et al. showed that by combining PRP with autologous bone in 
mandibular continuity defects resulted in significantly faster radiographic maturation and a 
histomorphometrically denser bone regeneration (Marx et al., 1998).  
In 2000 – 2010 authors observed various healing effects of PG, for instance that chronic 
lower extremity ulcers (diabetic, post-traumatic, vascular) reepithelialized faster with the 
course of twice-daily wound treatment with platelet releasate as compared with similar 
wounds treated with a placebo. The supernatant or releasate of the platelet gel was able to 
promote dose-dependent proliferation and changes in gene expression as well as in 
metabolic activities related to protein synthesis (Junger et al., 2000;Valencia et al., 2001; Fang 
& Galiano, 2008; Bernuzzi et al., 2010; Ficarelli et al., 2008; Chen et al., 2010). The platelet 
concentrate was used for healing skin, soft tissue wounds, fractures, surgical injuries, 
diabetic ulcers, dental, oral and maxillofacial settings (Altman et al., 2001; Margolis et al., 
2001; Anderson &Baker, 2003; Castro, 2004; Belli et al., 2005; Burkus, 2005; Carreon et al., 
2005; Sclafani et al., 2005; Trowbridge et al., 2005; Brown et al., 2006; Driver et al., 2006; 
Savarino et al., 2006; Rozman & Bolta, 2007; Borzini & Mazzucco 2007; Smrke et al., 2007; 
Cieslik-Bielecka et al., 2008;). 
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Novel strategies of platelet gel application in cardiology were under investigation in the 
year 2004. Studies evaluated the use of platelet gel in the case of myocardial injury, in order 
to promote remodelling through the regeneration of myocytes, the induction of 
angiogenesis and the restoration of a normal extracellular matrix composition (Mogan & 
Larson, 2004; Balbo et al., 2010;). 
PG/PRP was further intensively studied. Human umbilical vein endothelial cells (HUVECs) 
were isolated from umbilical cord veins and grown in appropriate conditions in vitro. The 
platelet gel-released supernatant was able to induce proliferation and to stimulate motility 
and the invasiveness of HUVECs. Higher concentrations of PG induced a reversion of the 
stimulatory processes. It became clear that different concentrations of the platelet growth 
factors do not have the same efficacy in inducing these processes: excessively high 
concentrations can have an inhibitory effect on the processes. Further studies are necessary 
to reach a better understanding of these complex biological processes (Rughetti et al., 2008). 
PG treatment in 2008 revealed a unique capacity of articulating a pro-inflammatory and pro-
angiogenic cytokine profile in human peripheral blood mononuclear cells, co-cultured with 
PG, which may partially explain the clinical success of PG application in a wide range of 
diseases (Naldini et al., 2008). 
A 1-year retrospective review of a cardiac surgery patient in 2008 showed that the treatment 
group with PG significantly shortened the duration of intensive care and decreased the total 
length of stays as well as decreased postoperative blood loss, compared with the control 
group. In addition, the treatment group had no reported incisional wound infections 
(Englert et al., 2008; Gunaydin et al., 2008). 
2. Platelet structure and physiology 
Platelets are not ˝real˝ cells but rather non-nuclear cellular fragments derived from the 
megakaryocytes in the bone marrow through controlled cellular fragmentation, 
followed by their release into circulation (Jurk & Kehrel, 2005). A healthy adult aged 
between 30 and 70, weighing 70 kg, has in total about 1,300-1,500 grams of platelets 
(thrombocytes); 40% of them in the spinal bone marrow, 25% in the ribs and sternum, 
15% in the pelvis, 10% in the skull, and 10% in other bones. Progenitor cells of the 
thrombocytic lineage develop in the same way as other immature cells of bloodlines in 
the bone marrow, originating from the common hematopoietic stem cell. When 
immature cells differentiate into directed stem cells they are morphologically 
recognizable as the progenitor cells of thrombocytic lineage. The progenitor cell is the 
megakaryoblast, with 21-50 mm diameter, which develops from the common myeloid 
progenitor named CFU-GEMM. The megakaryoblast gives rise to the promegakaryocyte 
and then the megakaryocyte - the largest cell in the bone marrow with 70-100 mm in 
diameter. Several growth factors are involved in the platelet differentiation, among 
which the thrombopoietin plays the most decisive role, inducing thrombopoiesis in a 
negative loop fashion by binding to the thrombocytes when they are present in 
sufficient numbers, thus decreasing their production from the HSCs in the bone marrow 
(See Figure 1). 
There are 1/3 immature and 2/3 mature elements of megakaryocyte lineage in the bone 
marrow. Thrombocytes are formed by the breaking off of small fragments of the 
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megakaryocyte cytoplasm. Each megakaryocyte gives rise to 2,000 to 4,000 thrombocytes. 
The development of the megakaryocyte from the megakaryoblast takes 4-5 days, and the 
life-span of a thrombocyte is 7-10 days. The number of thrombocytes in the peripheral blood 
is 150-350 x 10E9/L. If functionally classified, platelets consist of various molecules: 
membrane proteins 3%, signalling proteins 24%, cytoskeletal 15%, vesicular 6%, 
extracellular 4%, mitochondrial 7%, protein processing 22%, metabolic enzymes 6%, 
unknown 4%, miscellaneous 5.5% and nuclear proteins 3.5% (Garcia et al., 2004).  
 
 
 
Fig. 1. Thrombopoiesis in the bone marrow 
As mentioned previously, platelets are primarily specialized secretory cells that release the 
contents of their intracellular granules in response to activation. Beside their well known 
function in haemostasis where they prevent blood loss at the sites of vascular injury, they 
also release substances that promote tissue repair and influence the reactivity of vascular 
and blood cells in angiogenesis and inflammation (Jurk & Kehrel, 2005). At the site of the 
injury, platelets release an arsenal of potent inflammatory and mitogenic substances which 
are involved in all aspects of the wound healing process. Based on these facts, platelet 
releasate in the form of activated platelet gel has been extensively used for the topical in loco 
therapy of various clinical conditions (Borzini & Mazzucco, 2007). The purpose of this 
chapter is to review the current laboratory and clinical findings related to the therapy of 
these diseases with the use of platelet gel derived growth factors. 
3. Platelet activation 
Platelets are normally circulating in the blood in their resting form (Gresele at al., 2002). 
Non-activated platelets contain a complete array of presynthesized protein molecules 
important for platelet function, among which the high presence of cytoskeletal proteins, 
signalling proteins, membrane proteins, protein processing proteins and cytoskeleton 
regulatory proteins is noted (Garcia et al., 2004; Anitua et al., 2004). These molecules are 
synthesized already in the megakaryocytes and packaged into the granules. Three major 
storage compartments in platelets are alpha granules, dense granules and lyzosomes. The 
majority of the substances are contained in alpha granules (Rendu & Brohard-Bohn, 2001). 
(See Tab. 1). 
Hematopoietic Stem Cell 
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Category Term Biological activities 
Adhesive proteins
VWf + propeptide, Fg, Fn,Vn,TSP-1, 
laminin-8 
Cell contact interactions, 
clotting, extracellular matrix 
composition 
Clotting factors 
and associated 
proteins 
Factor V/Va, factor XI, multimerin, 
gas6, protein S, high-molecular weight 
chininogen, antithrombin, tissue factor 
pathway inhibitor (TFPI) 
Thrombin production and its 
regulation, angiogenesis 
Fibrinolytic factors 
and associated 
proteins 
Plasminogen, PAI-I, u-PA, osteonectin, 
ǂ2-antiplasmin, histidine rich 
glycoprotein, TAFI, ǂ2-macroglobulin 
Plasmin production and 
vascular remodelling 
Proteases and anti-
proteases 
Tissue inhibitor of metalloprotease-4 
(TIMP-4), matrix metalloproteinases 
MMP-1,-2,-3, -4, -9, platelet inhibitor of 
FIX, protease nexin-2, C1 inhibitor, ǂ1-
antitripsin 
Potentiation of aggregation, 
angiogenesis, vascular 
modelling, regulation of 
coagulation, regulation of 
cellular behaviour 
Growth factors, 
cytokines and 
chemokines 
PDGF, TGFǃ1 and 2, EGF, IGF-1, VEGF 
(A and C), bFGF and FGF-2, hepatocyte 
GF, RANTES, IL-8, MIP-1ǂ, growth 
regulated oncogene-ǂ, ENA-78, MCP-3, 
angiopoietin-1, Il-1ǃ, IGF BP-3, 
neutrophile chemo active protein 
Chemotaxis, cell 
proliferation and 
differentiation, angiogenesis 
Basic proteins and 
others 
PF4, ǃ-thromboglobulin, platelet basic 
protein, connective tissue activating 
peptide III, neutrophile activating 
peptide-2, endostatins 
Regulation of angiogenesis, 
vascular modelling, cellular 
interactions. Endostatin is an 
endogenous inhibitor of 
angiogenesis and the growth 
of both primary tumors and 
metastasis. 
Anti-microbial 
proteins 
Thrombocidins 
Bactericidal and fungicidal 
properties 
Others 
-chondroitin 4-sulfate, albumin, 
immunoglobulins 
Diverse 
Membrane 
glycoproteins 
ǂIIbǃ3, ǂ ǃ3, GPIb, PECAM-1, most 
plasma membrane constituents, 
receptors for primary agonists, CD40L, 
tissue factor, P-selectin 
Platelet aggregation and 
adhesion, endocytosis of 
proteins, inflammation, 
thrombin generation, 
platelet-leukocyte 
interactions 
Table 1. The contents of the platelet alpha-granules 
When adhered to exposed endothelium or activated by agonists, platelet change their shape 
and secrete the contents of the granules (including ADP, fibrinogen and serotonin), which is 
followed by the platelet aggregation. The initiation of the signalling event within the platelet 
leads to the reorganization of the platelet cytoskeleton , which is seen as an extremely rapid 
shape change (See Figure 2).  
www.intechopen.com
 
Advances in Regenerative Medicine 324 
 
 
 
Legend: Resting platelets are smooth and disc shaped (left). Activated platelets have an irregular shape with many 
protruding pseudopodia (right). 
Fig. 2. Platelets in their resting form and at the beginning of the activation. 
 
 
 
 
Fig. 3. Schematic representation of intracellular events during platelet activation - ”outside 
in” and “inside out” signalling 
Initiation of the signalling event within the platelet leads to the reorganization of the platelet 
cytoskeleton , which is seen as an shape change. Aggregation of platelets is mediated by 
molecules of fibrinogen or vWf, which connect platelets by bridging complexes of 
glycoprotein IIb/IIIa (integrin ǂIIb3) on adjacent platelets, forming a platelet aggregate. In 
order to bind the fibrinogen and vWf, GP-IIb/IIIa initially has to be converted from a low 
affinity/avidity state to a high affinity/avidity state by a process described as “inside-out 
signalling” that is initiated during and after platelet activation. Some of the substances 
GP I/V/IX 
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released by these cells – in particular adenosine diphosphate, serotonin, thromboxane and 
others – can, in an autocrine and paracrine fashion, further enhance platelet activation and 
aggregation (See Figure 3.). Under these conditions there is also activation of the coagulation 
cascade; therefore thrombin is formed, which also markedly stimulates the platelet 
activation in a positive feedback loop fashion (Gresele et al., 2002). 
4. Platelet receptors and antigens  
It has been proposed that the original function of the mammalian platelets resembled the 
function of primitive haemocytes in certain lower organisms such as caterpillars, in which 
they mostly act as a defence against foreign organisms by adhering and aggregating to 
foreign bodies. This is probably the reason why human platelets also possess many features 
of classical inflammatory cells. As such, they can undergo chemotaxis, release potent 
inflammatory mediators such as platelet factor PF4 and histamine, they can phagocytose 
foreign particles, interact with neutrophils, stimulate basophiles, excrete a number of 
mediators, cytokines, growth factors and other proteins and even interact with bacteria and 
parasites. Platelet membranes also bear some immune molecules, such as MHC Class I 
molecules, Fc receptors and complement binding molecules. The platelet membrane also 
incorporates AB0 and some other polysaccharide blood group Antigens, which are very 
important in blood transfusion (Rožman, 2002).  
The membrane of the resting platelet can modify considerably after the activation following 
adhesion. This stimulus causes numerous intracellular molecules that are a part of the 
lyzosomes, granules and other cellular compartments, to appear on the platelet surface. 
These molecules are therefore considered as markers of platelet activation. A short 
description of more than 45 distinctive platelet membrane structures found on resting 
platelets is given in Table 2. They are usually divided into five groups: adhesion molecules, 
immune molecules, receptors, blood group antigens and some other molecules. 
An extensive review of all molecules found on platelets and their precursors is given in 
references (Kishimoto et al., 1997). The CD designations of all integral molecules of the 
platelet membrane, as agreed upon at the 9th HLDA (Human Leukocyte Differentiation 
Antigens) workshop in 2010., can also be found on the internet addresses: http://hcdm.org. 
Many antigenic systems that are typical for erythrocytes and leukocytes, are also present on 
platelet membranes, including ABO and HLA antigens. Some others are exclusively found 
on platelets and their precursors. They are called human platelet alloantigens (HPA) and 
located on the platelet glycoproteins GPIa/IIa, GPIIb/IIIa and GPI/V/IX as a polymorphic 
part of the aminoacid chain. These polymorphisms are usually caused by a single nucleotide 
and the consequent aminoacid substitutions. The polymorphisms that cause 
alloimmunisation following transfusion and pregnancy were classified into the 
immunogenetic system of HPA (human platelet alloantigens) (Santoso & Kiefel, 1998). (see 
Table 3. and EMBL EBI immune polymorphysm database at the  http://www.ebi.ac.uk). 
For transfusion and transplantation, AB0, HPA and HLA antigens are important due to their 
capability of inducing an immune response in antigen- negative recipients. This could play a 
role in the allogeneic platelet gel settings, but surprisingly we could not find any immune 
consequences of the allogeneic platelet gel use in observed patients, treated topically with 
allogeneic platelets, as will be discussed later. 
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Group SUBGROUP Members Characteristics and function 
1.
 A
D
H
E
S
IO
N
 M
O
L
E
C
U
L
E
S
 
Integrins  
CD41 (Integrin ǂIIb 
subunit, GPIIb) 
Associates with GPIIIa into GPIIb/IIIa complex. 
The complex binds fibrinogen, vWf, fibronectin, 
vitronectin, thrombospondin 
CD61 (Integrin ǃ3 
subunit) 
GPIIIa; associates with CD41 (into the GPIIb) or 
CD51 (into the vitronectin receptor) 
CD49a (Integrin ǂ1 
subunit) 
Associates with CD29 (ǃ1 subunit) into VLA-1 
(GPIIa), binds to collagen and laminin 
CD49b (integrin ǂ2 
subunit)  
GPIa or VLA-2ǂ, associates with CD29 (GPIIa), 
binds collagen, laminin,  
CD49e (integrin ǂ5 
subunit) 
ǂ subunit of VLA-5 (vitronectin receptor), GPIc' 
subunit, of GPIc'/IIa, binds fibronectin 
CD49f (integrin ǂ6 
subunit) 
VLA-6ǂ subunit, GPIc, associates with CD29 (1) 
into VLA-6 (CD49f/CD29), binds laminin 
CD29 (integrin ǃ1 
subunit) 
Associates with CD49a in VLA-1 integrin (GPIIa) 
on platelets 
CD51 (integrin ǂV 
subunit) 
Associates with CD61 into the vitronectin 
receptor. A receptor for RGD-containing proteins 
(fibrinogen, vWf, fibronectin, laminin, 
thrombospondin). 
Selectins CD62 (P-selectin) 
Binds sialyl Lewisx, mediates the interaction of 
platelets with neutrophils, monocytes and a 
rolling interaction of neutrophils on 
 endothelium 
Leucine-rich 
proteins 
(GPIb-IX-V 
complex) 
CD42bǂ (GPIbǂ) Binds to the von Willebrand factor, receptor for 
thrombin 
CD42bǃ (CD42c) 
(GPIbǃ) Subunits of the GPIb-IX-V complex, bind to the 
von Willebrand factor CD42d (GPV) 
CD42a (GPIX) 
Ig – 
superfamily 
CD54 (ICAM-1) 
Interactions with integrins, receptor for 
rhinovirus 
CD31 (PECAM-1) 
Interactions with integrins, inhibiting 
neutrophile migration 
CD44 variants CD44 isoforms Adhesion to the extracellular matrix 
TM4 
superfamily 
CD9 
Tetra spanning membrane protein, regulation of 
integrin function 
CD165 (AD2, gp37, 
A108) 
Adhesion molecule, thymocytes/ thymic 
epithelium 
2.
 I
M
M
U
N
E
 M
O
L
E
C
U
L
E
S
 MHC class I. HLA-A, B, C Immune recognition 
Fc receptors CD32 (FcRII) Low affinity Fc receptor for aggregated 
Ig/immune complexes; activation 
C receptors C1q-, C2-, C4-receptors  Complement receptors 
Regulation of 
complement 
activation 
CD55 - DAF (decay acc. 
factor)  
Blocking and deactivating components of 
complement and inhibition of lysis 
CD59 - MIRL 
C8bp (C8-binding 
protein) 
CD46 - MCP (membr. 
cof. prot.) 
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3.
 R
E
C
E
P
T
O
R
S
 
Receptors for 
primary 
agonists 
Medium affinity 
thrombin rec. 
Mediate activation by agonistic ligands through 
different mechanisms 
High affinity thrombin 
rec. 
Epinephrine receptor 
TX A2 - thromboxane 
receptor 
PAF receptor 
ADP receptor 
PAF receptor 
Serotonin receptor 
Vasopressin receptor 
Inhibitory 
receptors 
2 adrenoreceptor 
Inhibit platelet activation 
Adenosine receptor 
Prostaglandin D2 
(PGD2) rec. 
Prostaglandin I2 (PGI2) 
rec. 
Multipurpose 
receptors 
CD36 (GPIV) 
Adhesion receptor for collagen and 
thrombospondin, receptor for  
Plasmodium falciparum, macrophage  
scavenger receptor 
Other 
receptors 
CD151 (PETA-3) Activates platelets upon stimulation with MAbs 
CD110 (TPO R, MPL) 
Thrombopoietin receptor,  
megakaryocyte proliferation and  
differentiation 
CD23 (FcRII) C-type lectin, low affinity receptor for IgE 
4.
 B
L
O
O
D
 
G
R
O
U
P
 
A
N
T
IG
E
N
S
 
AB0 A,B,H 
Oligosaccharides 
Le Lea, Leb 
Ii  I,i 
P P 
5.
 O
T
H
E
R
 M
O
L
E
C
U
L
E
S
 
 
Constitutive 
glycosphyngol
ipid 
CDw17 (lactosyl 
ceramide) 
Activation, release of granules 
Oligosacchari
des 
CD60 Oligosaccharide, present on gangliosides 
ǂ-granules 
proteins 
GMP-33 Translocated to the cell surface after activation 
Lyzosomes 
proteins 
CD107a,b (Lyzosomes-
associated membrane 
proteins LAMP-1&2) 
Liposomal membrane protein translocated to the 
cell surface after activation  
TM4 
superfamily – 
other 
members 
CD63 (Granulophysin, 
LIMP) 
Tetra spanning membrane protein, liposomal 
membrane protein translocated to the cell surface 
after activation  
CD82  
Tetra spanning membrane protein, suppresses 
metastasis, transduce signals in B, T cells and 
monocytes 
GPI-linked 
proteins 
CD109 
Platelet activation factor, GR56,  
Gova/b alloantigen on platelets 
Table 2. Molecules on the non-activated platelet membrane 
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System Antigen 
Phenotype
frequency*
Glycoprotein
Nucleotide 
Change* 
Aminoacid 
change 
CD 
HPA-1 
HPA-1a 
HPA-1b 
97.9% 
28.8% 
GPIIIa 
T176 
C176 
Leucine33  
Proline33  
CD61 
HPA-2 
HPA-2a 
HPA-2b 
>99.9% 
13.2% 
GPIbǂ C482 
T482 
Threonine145  
Methionine145  
CD42b 
HPA-3 
HPA-3a 
HPA-3b 
80.95% 
69.8% 
GPIIb 
T2621 
G2621 
Isoleucine843  
Serine843  
CD41 
HPA-4 
HPA-4a 
HPA-4b 
>99.9% 
<0.1% 
GPIIIa 
G506 
A506 
Arginine143  
Glutamine143  
CD61 
HPA-5 
HPA-5a 
HPA-5b 
99.0% 
19.7% 
GPIa 
G1600 
A1600 
Glutamic acid505  
Lysine505  
CD49b 
 HPA-6bw 0.7% GPIIIa 
G1544 
A1544 
Arginine489  
Glutamine489  CD61 
 HPA-7bw 0.2% GPIIIa 
C1297 
G1297 
Proline407  
Alanine407  CD61 
 HPA-8bw <0.01% GPIIIa 
C1984 
T1984 
Arginine636  
Cysteine636  CD61 
 HPA-9bw 0.6% GPIIb 
G2602 
A2602 
Valine837  
Methionine837  CD41 
 HPA10bw <1.6% GPIIIa 
G263 
A263 
Arginine62  
Glutamine62  CD61 
 HPA11bw <0.25% GPIIIa 
G1976 
A1976 
Arginine633  
Histidine633  CD61 
 HPA-12bw 0.4% GPIb G119 
A119 
Glycine15  
Glutamic acid15  CD42c 
 HPA-13bw 0.25% GPIa 
C2483 
T2483 
Threonine799  
Methionine799  CD49b 
 HPA-14bw <0.17% GPIIIa 
AAG1909-1911 
deletion 
Lysine611  
deletion  CD61 
HPA-15 
HPA-15a 
HPA-15b 
81% 
74% 
CD109 
C2108 
A2108 
Serine703 
Tyrosine703 
CD109 
 HPA-16bw
<0.1% GPIIIa 
C497 
T497 
Threonine140  
Isoleucine140 
CD61 
 HPA-17bw
<0.1% GPIIb/IIIa 
C662 
T662 
Threonine195  
Methionine195 
CD61 
 HPA-18bw
<0.1% GPIa 
G2235 
T2235 
Glutamine716  
Histidine 716 
CD49b 
 HPA-19bw
<0.1% GPIIIa 
A487 
C487 
Lysine137  
Glutamine 137 
CD61 
 HPA-20bw
<0.1% GPIIb 
C1949 
T1949 
Threonine619  
Methionine619 
CD41 
 HPA-21bw
<0.1% GPIIIa 
G1960 
A1960 
Glutamic acid628  
Lysine628 
CD61 
*Nucleotide change - numbers are given in relation to the reference sequence in the NCBI database 
Table 3. Human platelet alloantigens (HPA) (Modified from Metcalfe et al. 2003 and IPD HPA 
database http://www.ebi.ac.uk/ipd/hpa/freqs_1.html  
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5. Platelet growth factors 
As already stated, intact platelets contain alpha-granules and other granular bodies in which 
important mediator molecules are stored, and are released from the platelet following 
activation. Among these are the growth factors (GFs), which when released from activated 
platelets, exhibit an extensive tissue forming ability, such as the initiation and modulation of 
wound healing in both soft and hard tissues (Anitua et al., 2004; Harrison & Cramer, 1993; 
Lacoste et al., 2003; Weibrich et al., 2002). (See Table 1. and Table 4.)  
 
IL-1ß, Interleukin 
1beta 
 stimulates lymphocyte proliferation  
 influences collagenase activity 
IL-8, Interleukin 8 
 chemotactic for all known types of migratory immune cells 
 specifically activates neutrophile granulocytes 
 mitogen for epidermal cells 
EGF–ß, Epidermal 
growth factor (beta-
Urogastron) 
 stimulates re-epithelization, angiogenesis, and collagenase activity 
bFGF/ FGF-2, 
Fibroblast growth 
factor (basic) 
 stimulates angiogenesis, endothelial cell proliferation , collagen 
synthesis, wound contraction, matrix synthesis, epithelization, 
keratinocyte growth factor production 
aFGF/ FGF-1, 
Fibroblast growth 
factor (acidic) 
 most potent GF identified thus far for skin keratinocytes playing 
role in tissue repair following skin injuries. 
KGF/ FGF-7 
Keratinocyte growth 
factor 
 growth and development of progenitors of granulocytes and 
macrophages, stimulates myeloblasts and monoblasts and triggers 
their irreversible differentiation, synergises with EPO in the 
proliferation of erythroid and megakaryocytic progenitor cells, in 
combination with another colony stimulating factor, M-CSF, 
synergically suppresses the generation of macrophage-containing 
cell colonies 
 for some types of blast cells acute myeloid leukemia acts as an 
autocrine mediator of growth.  
 a strong chemoattractant for neutrophils, enhances microbicidal 
activity, oxidative metabolism, and phagocytic activity of 
neutrophils and macrophages, improves their cytotoxicity 
GM-SCF/ CSFα, 
granulocyte/macropha
ge colony-stimulating 
factor alpha 
 stimulates both the proliferation and the differentiated function in 
osteoblasts. 
IGF-1 
Insulin-like growth 
factor 
 a growth factor for normal fibroblasts, promotes the synthesis of 
collagenase and prostaglandin E2 in fibroblasts, may function also 
as an autocrine growth modulator for human chronic lymphocytic 
leukemia cells in vivo, an autocrine growth modulator for 
neuroblastoma cells, the autocrine growth-promoting activity is 
inhibited by IL4. 
TNF- α 
Tumor necrosis 
factor alpha 
 Besides its immune functions, TNF is a potent promoter of 
angiogenesis in vivo. TNF-alpha is a growth factor for human 
fibroblasts, where it promotes the synthesis of collagenase and 
prostaglandin E2 
www.intechopen.com
 
Advances in Regenerative Medicine 330 
 promotes the proliferation of astroglial cells and microglial cells 
and therefore may be involved in pathological processes such as 
astrogliosis and demyelinisation.  
PDGF A 
Platelet derived 
growth factor A 
 PDGF isoforms are potent mitogens for connective tissue cells, 
including dermal fibroblasts, arterial smooth muscle cells, 
chondrocytes and some epithelial and endothelial cells 
 chemotactic and mitogenic for fibroblasts and smooth muscle cells, 
neutrophils and mononuclear cells 
 activates TGF-ǃ, stimulates neutrophils and macrophages, 
stimulates chemotaxis, mitogenesis of fibroblasts and smooth 
muscle cells, collagen synthesis and collagenase activity, 
angiogenesis 
 a major mitogen for connective tissue cells and certain other cell 
types 
 stimulates cell growth, but also changes cell shape and motility; 
induces the reorganization of the actin filament system and 
stimulates chemotaxis, i.e., a directed cell movement toward a 
gradient of PDGF  
PDGF B 
Platelet derived 
growth factor B 
 regulates the proliferation and the differentiation of multiple cell 
types. TGF found in platelets is subdivided into TGF ǂ and , 
which are the more generic connective tissue growth factors 
involved with matrix formation influencing osteoblasts to lay 
down bone matrix through the process of osteogenesis.  
 TGF1 and TGF2 activate fibroblasts, endothelial and osteoprogenitor 
cells, chondroprogenitor cells and mesenchimal stem cells. A 
chondroprogenitor cell will further differentiate and produce the 
matrix for cartilage. A mesenchymal stem cell stimulated to mitose 
provides wound healing cells
TGF-α, 
Transforming 
growth factor alpha 
 stimulates mesenchymal, epithelial, and endothelial cell growth, 
endothelial chemotaxis 
TGF-ß1, 
Transforming 
growth factor ß1 
 stimulates monocytes to secrete FGF, PDGF, TNF– ǂ , Interleukin-1  
 stimulates fibroblast chemotaxis and proliferation  
 stimulates collagen synthesis  
 decrease dermal scarring 
VEGF/ VEP 
Vascular endothelial 
growth factor 
 highly specific mitogen for vascular endothelial cells 
 influences vascular permeability and is a strong angiogenic protein and 
probably also plays a role in neovascularisation under physiological 
conditions 
 in endothelial cells, VEGF induces the synthesis of von Willebrand 
factor.  
 a potent chemoattractant for monocytes and thus has procoagulatory 
activities.  
 in microvascular endothelial cells induces the synthesis of plasminogen 
activator and plasminogen activator inhibitor type 1. 
 induces the synthesis of the metalloproteinase, interstitial collagenase, 
which degrades interstitial collagen type 1, collagen type 2, and 
collagen type 3 under normal physiological conditions. 
Table 4. Platelet growth factors ( Modified from http://www.copewithcytokines.de/cope.cgi) 
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Growth factors modulate the functional activities of individual cells and tissues, mediate 
interactions between cells directly and regulate processes taking place in the extracellular 
environment in autocrine, paracrine, iuxtacrine or retrocrine fashion. GFs work by binding 
to specific cell surface receptors and can target cells in a number of recognized ways or 
modes. Release of these substances into the blood stream allows them to get to distant 
targets (endocrine mode), diffuse over short distances to affect other cells (juxtacrine mode), 
and to influence neighbouring cells (paracrine mode). Growth factors can even act on the 
cell in which they are produced (autocrine mode). These different modes are all likely to be 
operative during tissue repair.  
The most important GFs released by the platelets are PDGF (the platelet derived growth 
factor), TGF-ǂ & ǃ (transforming growth factor alpha & ǃ), EGF (epidermal growth factor), 
FGF (fibroblast growth factor), IGF (insulin growth factor), PDEGF (platelet derived 
epidermal growth factor), PDAF (platelet derived angiogenesis factor), IL-8 (interleukin-8), 
TNF-ǂ (tumour necrosis factor alpha), CTGR (connective tissue growth factor), GM-CSF 
(granulocyte macrophage colony stimulating factor), KGF (keratinocyte growth factor), and 
Ang-2 (angiopoetin) (Frechette et al., 2005; Borzini & Mazzucco, 2005; Westerhuis et al., 
2005; Everts et al., 2006) (see Table 4.). Beside these GFs, there are at least 60 different 
biologically active substances in the platelets that are involved in tissue repair mechanisms 
such as chemotaxis, cell proliferation and differentiation, angiogenesis, extracellular matrix 
deposition, immune modulation, antimicrobial activity, and remodelling (Borzini & 
Mazzucco, 2007). All these functions have been demonstrated in numerous in vitro (Phillips 
et al., 1994; Dankert, 1995; Brill et al., 2004; Cenni et al., 2005; Kark et al., 2006) and in vivo 
experiments (Debus et al., 2001; Kevy et al., 2004). 
6. Therapeutic platelet products 
Even the topically applied fibrin glue itself improves the haemostasis, reduces blood loss, 
and tightens the sealing of sutures due to fibrin formation, providing a stabilized matrix for 
ingrowing fibroblasts and therefore promoting the support of the granulation tissue, 
revascularization and re-epithelization. Further inclusion of growth factor containing 
platelets into this concept of tissue regeneration provided and increased tissue repair and 
regeneration. Various types of platelet products, such as platelet rich plasma, platelet-
leukocyte gel and platelet gel, derived from autologous or allogeneic peripheral blood, have 
been tested for tissue repair. 
6.1 Platelet-rich plasma  
Platelet-rich plasma (PRP) is defined as a portion of the plasma fraction of autologous blood 
having a platelet concentration above baseline. Usual product of blood banking is the 
allogeneic platelet concentrate or platelet-rich plasma, obtained from random blood donors. 
Autologous platelet rich plasma preparations involve the procurement of 50-100ml of blood 
drawn from the patient at the point of care. The blood is processed using PRP devices 
yielding 5-10ml of concentrated PRP (3 to 5X baseline levels). PRP serves as a growth factor 
vehicle and has both mitogenic and chemotactic properties. It contains a high level of 
platelets and a full complement of clotting and growth factors (Lacci & Dardik, 2010). The 
PRP is then activated and applied to the wound site or mixed with bone material for 
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implantation. This procedure is usually performed in under an hour by a well trained and 
qualified technician. 
6.2 Platelet gel  
Autologous platelet-gel (PG) is the result of harvesting one‘s own cells (platelets) that are 
concentrated by means of centrifugation and exposed to an agonist, which induces 
activation resulting in the release of intrinsic substances that are applied to the target area 
where they accelerate wound healing. Autologous PG is attractive because it concentrates a 
large number of biologically active substances, which are primarily proteins that participate 
in a complex series of mechanisms involved in inflammation and wound healing (Everts et 
al., 2006; Stammers et al., 2009; Tschon et al., 2011; Mehta & Watson, 2008). Lately, the 
possible use of allogeneic PG with similar results was demonstrated in our study (Smrke et 
al. 2007). 
6.3 Platelet-leukocyte gel  
Platelet-leukocyte gel contains high concentrations of platelets and leukocytes. As 
leukocytes play an important role in the innate host-defence, PLG might have antimicrobial 
properties. A unit of whole blood is centrifuged to obtain platelet-leukocyte-rich plasma (P-
LRP). The PLG is then formed by mixing P-LRP with a thrombin-calcium chloride 
preparation. Similar to PG, the treatment with PLG provides a source of concentrated 
platelets, with granules that contain growth factors. In addition the high content of non-
activated leukocytes, present in the PLG, promotes anti-microbial activity at the wound site 
through the destruction of bacteria and foreign materials and the removal of damaged tissue 
(Everts et al, 2006b; Everts et al. 2008). 
Platelet gel can be nowadays prepared using a range of commercially available instruments 
from a number of manufactures. There are no uniform manufacturing standards for platelet 
gel in existence, which has disturbed the classical blood banking. The existing literature 
adds controversies to the use of PLT concentrates. When talking about platelets and their 
products, a great number of variables have to be considered. These variables are mainly 
related to the PRP preparation methods, the type of activators used, intra- and inter-species 
variability, types of pathology to be treated, the ways and times of administration and the 
association of PRP or PG with other treatments. The improved knowledge on the variables 
affecting therapeutic efficacy will surely help in addressing the best combination of factors 
implied in the different steps of PLT concentrate preparation and use (Mazzucco et al., 
2009). 
7. Activation of PRP and the formation of the gel 
The typical source of platelet GFs is platelet-rich plasma (PRP) – Figure 4A. Platelet gel (PG) 
is formed after the PRP is exposed to a strong coagulation stimuli, which is usually the 
addition of thrombin and calcium (to counteract the anticoagulant citrate if plasma is 
citrated) ( Mazzucco et al., 2004; De Somer et al., 2006) or some other fibrinogen-digestion 
based activator, such as batroxobine from the viper Bothrops atrox snake venom ( Carr et al., 
2003; Mazzucco et al., 2008).  
Consequently, platelet activation and a coagulation cascade follow in a positive loop 
fashion, which finally results in the formation of a thrombus-like gelatinous substance – 
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platelet gel. (See Figures 4B, 4C). In the gel, activated platelets are trapped in a fibrin 
network and they release their active substances, which slowly diffuse into the 
surroundings. The final result – platelet gel – can be shaped according to the needs, put on 
different vehicles such as medical gauze or even advanced types of biocompatible carriers 
and scaffolds, such as fibrin or hyaluronic acid, and used topically. It can be used as a 
vehicle for the stem cells and ground cancellous bone transplant, allowing the formation 
and shaping of grafts with determined shapes (See Fig. 4D). 
 
     
          A.            B. 
     
           C.           D. 
Legend: A. Platelet rich plasma; B.Platelet gel; C: Microscopical view of the platelet gel. Inverted microscope 
Nikon Eclipsete 300, 10x enlarged.; D: Graft with the shape used for mandibular deffects, containing PG, stem 
cells and cancellous bone 
Fig. 4. Platelet gel 
At the beginning autologous PRP/platelet gel was developed as a by-product of 
multicomponent apheresis (Rosenthal et al, 1975). Later several systems became available to 
prepare PRP and from this, the platelet gel. These systems produce two- to six-fold platelet -
enriched concentrations. Very few data have been reported on the kinetics of growth factor 
release from PRP-gels. The bioavailability of growth factors in tissue healing depends on the 
amount of growth factors stored in the platelets but a portion of these is lost during platelet 
manipulation. In one report, three commercially available devices (Fibrinet, RegenPRP-Kit, 
Plateltex) and one manual procedure (home-made) were evaluated with reference to the 
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resulting platelet concentration, growth factor content and the kinetics of growth factor 
release from the gel. Similar methods for platelet gel preparation have revealed different 
performances concerning the growth factor recovery and the kinetics of its release from the 
gel. It is unclear whether these noticeable differences are important for clinical management 
(Mazzucco et al., 2009). 
Some research groups have successfully engineered kits for platelet gel formation, such as 
REGENLAB® and PLATELTEX®, which include sodium carboxymethylated cellulose fibres 
(Hydrofibre™) as a biocomposite-scaffold, entrapping human platelets in PRP. The 
PLATELTEX® activation kit, popular in Europe, ensures very rapid gelation and the 
production of platelet and fibrin gel for acute and chronic ulcer treatment. This reduces 
spillage of the gel during topical application. The new generation of PRP activation, 
provides for excellent platelet recovery, collection efficiency and PDGF-AB availability. 
Gelation of the PRP is induced by the enzyme batroxobin, which does not exert 
pharmacological activity after topical gel administration. In Europe, clinical trials have been 
authorised using PRP-gel preparation including activation with batroxobin. PRP-gel has not 
been considered a somatic cell therapy product. 
Platelets treated with thrombin become activated and they release their growth factors 
quickly. Furthermore, thrombin-platelet interaction is a physiological mechanism that 
hastens the clot-retraction rate. On the contrary, platelets treated with batroxobin do not 
become activated; they are passively entrapped within the fibrin network, and their growth 
factor release occurs slowly. In these conditions, the clot retraction takes longer to occur. 
According to these differences between thrombin and batroxobin, it is expected that 
batroxobin-induced PRP activation will tailor the slow release of the platelet content, thus 
providing longer in loco availability of trophic factors. In selected clinical conditions, this 
durable anabolic factor availability might be preferable to a quick thrombin-induced growth 
factor release (Mazzucco et al, 2008). 
An alternative means of PRP activation was documented in 2007, when PRP was pulsed 
with one 300ns pulse with an electric field of 30kV/cm, platelets aggregated and a platelet 
gel was produced (Zhang et al., 2008). 
The lack of effective delivery and the efficient targeting specificity limits clinical applications 
of platelet gel. In 2008, heparin possessing PDGF binding domain was crosslinked to the 
collagen-based demineralized bone matrix (DBM) for the delivery of human PDGF. In in 
vitro experiments, heparin improves the binding of PDGF to collagen. The in vitro activity 
assay indicates that the collagen-heparin-PDGF (CH-PDGF) complex promotes human 
fibroblasts to proliferate on collagen gel. In addition, CH-PDGF stimulates cells to migrate 
into DBM scaffolds after implantation. The histological analysis shows that CH-PDGF 
promotes the vascularization of the implants. In summary, heparin-DBM/PDGF could 
prevent the diffusion of PDGF, prolong its activity, and promote the cellularization and 
vascularization of the scaffold (Sun et al., 2009). 
Recent findings on multiple biological properties of human umbilical cord blood (UCB) and its 
high level of viral safety prompted some authors to investigate the characteristics of its 
platelets and the possibility of producing PG from cord blood. UCB-derived PG releases high 
levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor-BB 
(PDGF-BB), substantial amounts of fibroblast growth factor (FGF), hepatocyte growth factor 
(HGF) and transforming growth factor-beta 1 (TGFbeta1), and minimal amounts of PDGF-AB. 
These findings suggest that UCB-derived PG can be a preferable tool for tissue engineering 
applications where high levels of VEGF and PDGF may be desirable (Parazzi et al., 2010). 
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8. The results of recent clinical research 
The results of clinical research indicate that platelet-derived growth factors act in synergy 
with plasma-derived factors to activate a complex network of autocrine functions that 
modulate and enhance healing. Therefore, autologous platelet rich plasma (PRP) in the form 
of activated platelet gel and recombinant morphogenic proteins have been used for healing 
all kinds of tissues with various results. 
8.1 Chronic wounds  
When the fibroblasts were sealed in the wound with fibrin to which platelet releasate was 
added, a cellular infiltrate that had characteristics of granulation tissue invaded the wound 
space. Platelet releasate appeared to be an additional requirement for the early induction of 
granulation tissue and for enhanced granulation tissue accumulation. It is now widely 
accepted that the correct strategy to promote the wound-healing cascade is to prepare an 
autologous PRP/platelet gel that contains growth factors, and administer it directly to sites 
of surgical interventions or injuries. 
Patients suffering from diabetes mellitus, are seventeen times more likely to develop 
gangrene and five out of six major limb amputations occur in diabetic patients. In the United 
States, the diabetic foot problem accounts for 20% of all diabetic hospital admissions and 
50% of all non-traumatic amputations. Ulcers occur in 15% of diabetics, and 6-20% of all 
hospitalized diabetic patients have foot ulcers. The topical use of platelet rich plasma may 
play an important role in the initiation of the repair process of chronic wounds. Many 
patients can be treated at home without difficulty, requiring only periodic outpatient 
examination (Steed et al., 1992; Millington and Norris, 2000; Borzini, 2006). Although some 
of the earlier studies resulted in poor outcomes (Reutter et al.,1999), newer studies tend to 
produce much better results. 
8.2 Bone  
Platelet gel is very effective in formation of new bone when applied together with cancellous 
bone containing stem cells for treatment of non healing of long bone fractures (Smrke et al., 
2007). Platelet gel enhanced the bone formation contrary to the using of plasma alone as 
measured by quantity of incorporated bone both in vitro and in vivo (Geuze et al., 2009). In 
an article presented in 2010, 115 patients with finger amputations or wounds were treated 
with platelet gel. Loss of bone tissue represented an obstacle to the total tissue recovery, but 
the aesthetic results were satisfactory in nearly all cases, the recovery of soft tissue in all 
patients ranged from 80 to 100% (Balbo et al., 2010). However, platelet gel was ineffective for 
the spinal fusions where it failed to enhance fusion rate when added to autograft in patients 
undergoing instrumented posterolateral spinal fusion so several authors do not recommend 
its use to supplement autologous bone grafting during instrumented posterolateral spinal 
fusion ( Castro, 2004; Burkus, 2005; De Somer et al., 2006; Savarino et al., 2006). 
8.3 Tendons and ligaments  
Tendons and ligaments naturally have poor blood supply. Damage most often occurs in the 
knee, ankle, shoulder, elbow, wrist, biceps, calf, hamstrings and Achilles tendons. The use of 
platelet gel has been generally well tolerated by the patients and it resulted in significant 
increase of healing parameters. Platelet injection therapy has changed the way orthopedic 
specialists treat sports injury patients. Usually PRP is injected into the damaged area using 
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minimally invasive protocols that involve ultrasonically guided platelet rich plasma (PRP) 
injections. (Everts et al. 2007; Everts et al.,2008; Gardner et al., 2006). 
8.4 Aesthetic surgery 
There is especially extensive marketing for the use of PRP in aesthetic surgery and lifting 
(Bhanot & Alex, 2002; Powell et al., 2001). Private organisations tend to offer this therapy 
throughout the world. They offer PRP delivery by various instruments into the skin tissues, 
rendering good aesthetic effects (see Figure 5). The indications include facelifts, browlifts, 
the creation of flaps, blepharoplasty, mammaplasties, and abdominoplasties. PRP enhanced 
grafts generally had a higher graft acceptance and better graft retention than traditional fat 
grafting techniques, along with decreased swelling and bruising in the donor sites (Sclafani 
et al., 2005;Brown et al, 2006). 
 
     
           A               B 
     
          C               D 
Legend: A: The instrument Mesogun for delivering PRP (U225)as marketed by company Boland; B: The needle 
depth can be accurately set for precise delivery; C: An example of kit for PRP preparation and application from 
Omnimed (Pty)., Ltd., JHB, South Africa; D: An example of platelet gel activation kit PLATELTEX® 
(http://www.bolandcell.co.za/platelet.htm)  
Fig. 5. Use of autologous platelet-rich plasma (PRP).  
8.5 Cardiovascular  
Wound infection is a devastating complication after cardiovascular surgery. This can lead to 
surgical reoperation, prolonged intensive care unit stay, and increased mortality promoting 
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the raising the cost of cardiac surgery while decreasing the patient quality of life. The 
antimicrobial action of white blood cells and platelets, both found in the platelet gel, may 
reduce the potential for infection to develop during cardiac surgery. Various protocols have 
documented such an improved healing of surgical wound in cardiac surgery (Mogan and 
Larson, 2004; Trowbridge et al,2005; Englert et al., 2008; Gunyaqdin et al., 2008) 
8.6 Oral and craniofacial surgery 
As mentioned, the oral surgeons were the leading community in the use of platelet gel for 
transplantation of artificial and natural grafts. Platelet gel reached a huge popularity in 
maxillofacial settings where it is considered standard treatment of bone defects, artificial 
endosseal implants, oral reconstructions, maxillary sinus augmentation, etc. (Marx et al., 
1998; Belli et al., 2005; Pomerantz and Dutton, 2005; Mendez et al., 2006). 
8.7 Other applications 
Platelet gel has been successfully used for ocular diseases, such as for enhanced healing of 
corneal surface and ocular surgery (Koffler, 2006; Liu et al.,2006; Lee & Kang, 2011). 
Lately, the studies of PG use addressed some unexpected fields of medicine. For instance, PG 
was used as a safe and effective tool in the management of mucosal skin lesions related to the 
graft- versus-host disease GVHD. Six patients with multiple lesions involving dermis, 
subcutaneous or oral mucosa and related to GVHD underwent PLT gel as local therapy. After 
the second PLT gel application, the pain disappeared in all cases and the granulation tissue 
was observed in the four patients, five of six patients showed a complete response, while one 
patient with a partial response died early from multiorgan failure (Picardi et al., 2010). 
Platelet gel mixed with centrifuged fat tissue has been successfully applied for the patients 
affected by Parry - Romberg Syndrome (progressive hemifacial atrophy and volumetric 
deficit), which is an uncommon degenerative and poorly understood condition. It is 
characterized by a slow and progressive atrophy affecting one side of the face. The atrophy 
progresses slowly for several years and becomes stable. After stabilization of the disease, 
plastic surgery of autologous fat grafts can be performed. Study suggested a therapeutic 
plan comprised of two sequential treatments: acquisition of platelet gel from a small volume 
of blood (9 ml) followed by the Coleman technique for reconstructing the three-dimensional 
projection of the face contour, restoring the superficial density of the facial tissues. The 
results obtained prove the efficacy of these two treatments combined, and the satisfaction of 
the patient confirms the quality of the results. (Cervelli & Gentile, 2009). 
Recently it is surprisingly becoming clear that platelets have a definite role in the cancer, 
which is probably due to their pro-angiogenesis stimulation and regulation of new blood 
vessel growth through numerous stimulators and inhibitors of angiogenesis, such as 
endostatin and VEGF, by several pathways. Cancer cells probably preferentially stimulate 
platelets to secrete their pro-angiogenic payload, which is counteracted by the anti-platelet 
agent aspirin that inhibits the platelet-mediated angiogenesis (Elisabeth et al., 2011). 
9. Pros and cons of platelet gel therapies 
The common advantages of the PG driven healing can be summarized as follows: there 
seems to be a complete absence of keloid formation, as far as pathologic hyperplasia, 
metaplasia or dyschromia of the healed lesion (Pomerantz et al., 2005, Lundblad & White, 
2005). Other advantages are comfort and pain diminution (Pomerantz et al., 2005, Mendez et 
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al., 2006), less oedema and ecchymosis (Powell et al., 2001; Mendez et al., 2006; Brown et al., 
2006). Particularly valuable advantages are reported through literature: reduced mortality 
after cardiac surgery (Trowbridge et al., 2005), reduced infection rate after cardiac and 
orthopaedic surgery (Gilsanz et al., 2001; Salvadè et al., 2010), reduced transfusion supply 
and hospital stay after orthopaedic surgery (Gardner et al., 2006), reduced amputation rate 
in diabetic foot (Knighton et al., 1990). PRP therapy became very popular in the USA, which 
was due to the fact that it attracted enormous attention after the Super Bowl finals in 2009, 
when the athletes promoted it on TV (Donald, 2011). 
Drawbacks of PG therapies are far less pronounced. It is interesting that besides the 
considerable variability of the clinical studies, PG therapy had practically no or only minute ill 
effects when compared to standard therapies. Owing to the high heterogeneity of the products, 
a need for standardization is a commonly shared sentiment. Heterogeneous production 
generates heterogeneous products which, in turn, have distinct biological properties and 
healing capacities (Zimmermann et al., 2003; Eppley et al., 2006; Fried et al., 2006). 
Considering that heterogeneity involves products, clinical conditions, tissues to be cared for, 
treatment protocols and probably many other minor variables, authors strongly support the 
project for the establishment of a clinical database in order to collect enough data for 
multivariate analysis of the clinical results (Kantor & Margolis, 2000). 
10. The dilemma of allogeneic vs. autologous platelet gel 
In the majority of clinical applications autologous platelets were used for the platelet gel 
formation. As mentioned previously, autologous PG products are prone to enormous 
variability, resulting in scientific scepticism and disbelief regarding the actual value of this 
method. In our study in 2007, we used instead allogeneic PRP. We reported a case of a 50-
year-old type II diabetic male with a comminuted fracture of the tibia and delayed union 
after insufficient initial osteosynthesis with a resulting pseudarthrosis, who was treated 
operatively by using a graft composed of allogeneic platelet gel mixed with autologous 
cancellous bone. Due to a history of diabetes, allogeneic instead of autologous platelets that 
were ABO and RhD matched, leukocyte depleted, irradiated and activated by human 
thrombin were used. No side effects were observed and no immune reactions such as 
platelet- or HLA-class I antibodies were detected (Smrke et al., 2007). 
We explored several advantages of allogeneic platelets, as compared to the classical 
autologous setting. Allogeneic platelet units from the blood bank are available in larger 
quantities, they are safe and affordable, they are highly standardized in terms of platelet, 
residual leukocyte and red blood cell content, the centrifugal forces used for their isolation, 
the temperature of the centrifugation, techniques of separation and processing and the 
composition of the preservative solution, as mandated by international standards in USA 
and Europe. In addition, they are constantly resuspended on agitators in a standard manner 
(Brecher, 2005; Council of Europe, 2011). On the other hand, autologous platelet 
preparations are subject to enormous variability, which hinders serious clinical studies. 
The extensive use of allogeneic platelets could, beside the regenerative medicine, influence 
the blood transfusion policies in future. The platelet units have a short shelf life of 3 – 7 days 
and are therefore prone to outdating, regardless of the best practices performed. In 2001 in 
USA, at least 1,234.000 out of a total of 12,898.000 produced platelet units (9.5%) were 
outdated and discarded (Sullivan et al, 2007). In another study, expiry rates of platelet units 
were different in various hospitals, ranging between 2% and 13.8% (Novis et al, 2002). It is 
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clear from these figures that a considerable amount of platelet units are routinely discarded, 
which could be reversed by the utilization of frozen units in regenerative purposes, such as 
platelet gel preparation.  
Besides, the use of platelet gel could have an important impact on economy of medicine. Let 
us focus only at the therapy of chronic wound with the platelet gel. Ulcer secondary to 
venous hypertension and venous insufficiency is the most common chronic wound with 57-
80% incidence of all chronic wounds. Average incidence is 15-30 in 100.000 persons and they 
account for nearly 70% of all leg ulcers (Margolis et al., 2001). All these conditions are more 
prevalent in elderly population, which represents 20% of the total, a figure that is likely to 
increase to 25% by 2020. In addition, the increased occurrence and longevity of these ulcers 
are further compounded by the detrimental effects ageing has on the skin and the wound 
healing process. Chronic wounds significantly impair the quality of life of more than 9 
million of people worldwide and account for a disproportionate share of healthcare 
expenditures: it is estimated that yearly treatment cost for health care systems averages 9 – 
12 k€ per each patient. Even with increasing knowledge and the development of more 
sophisticated interventions, many clinicians encounter wounds that are hard-to-heal where, 
despite best efforts, wound healing is prolonged or never achieved (Moffatt, 2008). Indeed, 
chronic and hard-to-heal wounds are a challenge to the health care professionals. Thus, in 
the frame of progressively ageing population, the efficient therapy for chronic wounds and 
tissue reparation promises improving life quality and combating rising healthcare costs. 
Currently available and practiced therapies such as wound dressings, pentoxifylline, laser 
and intermittent pneumatic compression treatments applied in concomitance with 
compressive bandages have shown rather disappointing overall outcomes except some 
encouraging results obtained by combination of compression and bilayer of artificial skin 
(Palfreyman et al., 2006).  
11. Conclusion 
Platelets are intriguing cellular particles that have, in the course of human and animal 
evolution, beside their specialisation into the haemostasis, kept some other abilities of 
their predecessors - universal blood cells – the abilities of immune defence and tissue 
forming. For the purpose of tissue forming, platelets can also be used therapeutically. 
Autologous or allogeneic blood can be used for this purpose and centrifuged to produce a 
platelet concentrate, which is then further in vitro activated to form a thrombus-like 
gelatinous substance – the platelet gel. Many in-vitro studies have established that 
platelet- derived growth factors accelerate proliferation of an array of cells involved in 
soft and bony tissue regeneration. These effects have also been evaluated and confirmed 
by numerous in vivo, both in animal and human clinical studies. Consequently, we can say 
that the platelet-derived products currently represent a valuable therapeutic modality, 
offering opportunities for various applications in regenerative medicine and tissue 
engineering.  
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